Which Herbs Actually Work for Chronic Lyme — and Should You Use Dry Herb, Tincture, or Liposomal?
Almost every chronic Lyme patient arrives with a bag of half-finished bottles. Cryptolepis. Japanese knotweed. Chinese skullcap. Artemisinin. Some helped. Some caused a week in bed. Most were never given long enough, or in the right form, to tell. This is our guide to what the botanical evidence actually shows, and to the sequence we use — dry herb first, then tincture, then liposomal — to find a patient’s true ceiling without setting them back.
A woman came to us last year carrying a shoebox. Inside were nineteen bottles. Six were unopened. Four had two doses missing — the two doses that had put her on the couch for a week. The rest were somewhere in between: started, tolerated, forgotten, restarted at a different dose, abandoned again. She had spent close to four thousand dollars on the contents of that shoebox, and she could not tell me whether a single herb in it had helped her.
This is the normal experience of herbal treatment for chronic Lyme disease. Not because the herbs are useless — several of them have genuinely interesting laboratory data behind them — but because they are almost always deployed without three things: a prepared terrain, a deliberate sequence, and an understanding of how much the form of a preparation changes what it does in the body.
“I’ve taken all of these. I still don’t know which ones work for me.”
That last point — form — is the one almost nobody explains, and it is the reason this article exists. A quarter teaspoon of Cryptolepis tincture is not a smaller version of a Cryptolepis capsule. It is a different intervention: different concentration, different absorption curve, different speed of onset, different likelihood of a reaction at three in the morning. And a liposomal preparation of the same herb is different again. Used in the wrong order, these differences are what turn a reasonable protocol into a shoebox.
What follows is long, because the subject is. If you want the practical core, it is this: start with the dry herb to find out whether the patient can tolerate the plant at all; move to tincture when you need real therapeutic pressure; reserve liposomal delivery for the deep, stubborn, tissue-sequestered end of the problem — and only once drainage and the nervous system are open enough to handle it. Everything else here is the reasoning behind that sentence, and the herb-by-herb detail to execute it.
What this guide covers
- Why herbs at all — the persister problem
- What the Johns Hopkins data really showed
- Why the terrain comes first
- Dry herb vs. tincture vs. liposomal
- Form comparison table
- Liposomal herbs: what is real, what is oversold
- The master herb table
- Herb-by-herb profiles
- A closer look at Cistus incanus
- How we actually build a protocol
- The mistake almost everyone makes: stopping
- Managing die-off and Herxheimer reactions
- What herbs cannot do
- Frequently asked questions
- References
Why Herbs at All? The Persister Problem
The case for botanical therapy in chronic Lyme does not begin with the plants. It begins with a gap in what antibiotics can do.
Borrelia burgdorferi is an unusually well-defended organism. It changes its surface proteins to stay ahead of antibody recognition. It leaves the bloodstream quickly and takes up residence in collagen-rich, poorly perfused tissue — joint capsule, tendon, fascia, the nervous system — where drug concentrations are lowest. It downshifts into round bodies and other dormant morphologies under stress. And it forms biofilm: a self-produced matrix that physically slows the entry of antimicrobials and shields the organisms inside from immune surveillance.
That last set of behaviours produces what microbiologists call persisters — not genetically resistant organisms, but metabolically dormant ones. Most antibiotics kill by interfering with processes that only happen in actively dividing cells: building a cell wall, synthesising protein, replicating DNA. A bacterium that has stopped doing those things is, for practical purposes, invisible to the drug. It is not resistant. It is simply not listening.
This is the mechanistic heart of why a patient can complete six weeks of doxycycline, feel genuinely better, and relapse four months later. The drug cleared the dividing population. The dormant fraction waited it out.
In laboratory culture, doxycycline and cefuroxime at clinically achievable serum concentrations (5 µg/mL) reliably kill log-phase, actively growing B. burgdorferi — but fail to eradicate stationary-phase cultures, which regrow on subculture. This is the single most reproducible finding in the persister literature, and it is the reason the search for non-antibiotic agents began.1,2
It is worth being precise about what this does and does not mean. It does not mean antibiotics are useless — in early, acute, localised Lyme they are genuinely curative and should be used without hesitation. It does not mean that every lingering symptom after treated Lyme is an ongoing infection; a great deal of persistent illness is immune and vascular rather than microbial, which is why we have written separately about the inflammatory and endothelial drivers behind chronic Lyme and long COVID. What it means is narrower and more useful: in the chronic case, killing what is dividing is not the whole job, and the agents that work on the dormant fraction are mostly not the agents in the standard playbook.
That is the gap botanicals were screened to fill.
Biofilm deserves more than the sentence it gets here, because it is both the best-characterised reason chronic infections survive treatment and the most oversold concept in the integrative supplement market. We have written a companion piece on exactly that — Why won’t my infection clear? Understanding biofilm in chronic Lyme and mold illness — covering what the matrix actually is, why it defeats antibiotics and the immune system, and which of the agents sold for it have real evidence behind them.
There is a second reason, and in our clinic it may matter more than the first. Long antibiotic courses do real collateral damage. We see the wreckage constantly: post-antibiotic SIBO, fungal overgrowth, mood dysregulation, insomnia that started during month eight of a two-year protocol and never left. The microbiome is not a bystander in Lyme recovery — it is part of the immune apparatus you are trying to restore. A therapy that reduces microbial burden while doing less damage to the ecosystem doing the recovering is worth something, even if its in-vitro potency is lower.
The goal is not a sterile patient. It is a patient whose immune system can hold the line.
What the Johns Hopkins Botanical Data Really Showed
Nearly every herbal Lyme protocol currently in circulation traces back, directly or indirectly, to one paper: Feng and colleagues, published in Frontiers in Medicine in 2020, out of Ying Zhang’s laboratory at Johns Hopkins.1 It is a genuinely useful study, and it is also the most consistently misquoted study in this field. Getting it right matters, because the shape of a protocol should follow the shape of the evidence.
What they did
The team screened fifteen agents — twelve botanical medicines plus three other natural antimicrobials — against both growing and stationary-phase (persister) B. burgdorferi, at extract concentrations of 1%, 0.5% and 0.25%. They then subcultured the treated samples for twenty-one days to see whether anything grew back. Growing back is the test that matters; killing most of a culture is easy, and sterilising it is not.
What they found
Seven of the fifteen showed strong activity against the stationary-phase organisms at 1%:
- Cryptolepis sanguinolenta (Ghanaian quinine)
- Juglans nigra (black walnut)
- Polygonum cuspidatum (Japanese knotweed)
- Artemisia annua (sweet wormwood)
- Uncaria tomentosa (cat’s claw)
- Cistus incanus (rock rose)
- Scutellaria baicalensis (Chinese skullcap)
One stood apart. Cryptolepis sanguinolenta was the only agent in the entire panel that produced complete eradication — no regrowth at twenty-one days — at 1%. Its minimum inhibitory concentration against growing organisms was 0.03–0.06%, an order of magnitude below the next-best botanical. At 0.5% it was close but not reliable: one of three samples regrew. Doxycycline and cefuroxime, tested in parallel, did not sterilise the stationary-phase cultures at all.
Two results in that paper are almost never mentioned by the protocols that cite it, and both are clinically relevant. First, Chinese skullcap and cat’s claw were the weakest of the seven, with roughly 59% and 49% of organisms still viable at 1% — they are frequently presented as interchangeable with Cryptolepis, and they are not. Second, teasel root and stevia were inactive, with MICs above 2%. Both are widely sold for Lyme.
You will see this study summarised as “herbs outperform antibiotics for Lyme.” That sentence is not supportable, and repeating it damages the credibility of everything else in the field.
The botanicals were tested at 1% w/v — roughly 10,000 µg/mL of crude extract. The antibiotics were tested at 5 µg/mL, a concentration a human being actually achieves in serum. That is an approximately 2,000-fold difference in mass. The honest reading is that these botanicals are active in a model where antibiotics fail, at concentrations whose achievability in human tissue is unknown. That is still an interesting and important result. It is not the same claim.
What has and has not happened since
The same laboratory published two earlier essential-oil screens that are worth knowing about, because they are the source of the biofilm data people often mistakenly attribute to the herbal extracts. Oregano, cinnamon bark and clove bud oils sterilised stationary-phase cultures at 0.05–0.1% and dissolved biofilm-like aggregates;2 a follow-up found garlic oil and cinnamaldehyde active at 0.05%.3 Those are essential oils, not tinctures, and they are not interchangeable with the herbs above.
What has not happened is the obvious next step. Six years after the 2020 paper — whose authors explicitly called for it — there is still no published animal study of Cryptolepis or any other botanical against B. burgdorferi, and no randomised controlled trial of any herbal protocol for Lyme disease in humans. A 2023 review of eighteen herbs used for persistent Lyme symptoms concluded plainly that in-vivo and clinical trial data are lacking.4
One retrospective analysis exists, comparing a nine-herb tincture against conventional antibiotics in 116 patients and finding comparable declines in a lymphocyte transformation test marker.5 It is retrospective, unblinded, unrandomised, has a ten-patient control arm, and reports no clinical symptom outcomes at all — the endpoint is a laboratory surrogate whose meaning in Lyme is itself contested. It is worth knowing that it exists. It is not worth building a protocol on.
We hold all of this loosely, and we think you should too. Not because the herbs do not work — we watch patients respond to them every week — but because “compelling laboratory data plus enthusiastic clinical adoption” is a combination that has fooled this field before.
Disulfiram is the closest recent example. It is a pharmaceutical rather than a botanical, so the parallel is not exact, but the shape is instructive: striking in-vitro persister-killing data, years of anecdotal use, and then a 2025 randomised trial in which only three of nine participants completed treatment at standard dosing.6 Worth noting — and this is the part that maps onto herbal practice — that trial used conventional full doses. We do use disulfiram occasionally, but only as a low-dose compounded preparation titrated slowly, which is a meaningfully different intervention and, in our hands, a far better tolerated one. The lesson is not that the agent is worthless. It is that dose, pacing and patient selection frequently matter more than the molecule, and that laboratory potency tells you very little about either.
Why the Terrain Comes First
Here is the mistake we correct most often, and it has nothing to do with which herb a patient chose.
They started killing before the body could handle what killing produces.
When you disrupt a microbial population, you release its contents: lipoproteins, endotoxin, cell-wall fragments, sequestered metals, whatever the organisms had been holding. The body has to process and excrete that material. If the liver is congested, the bile is sluggish, the gut is inflamed and the lymphatics are static, that debris does not leave — it recirculates. The patient does not experience this as progress. They experience it as being hit by a truck.
This is what a Herxheimer reaction largely is: not evidence that a herb is “working,” but evidence that the rate of release has outrun the rate of clearance. Treated as a badge of honour, it drives patients into weeks of setback and, eventually, into the shoebox.
In our practice the order is fixed even when the specifics are not: nervous system regulation first, then drainage and binders, then gut restoration, and only then infection targeting. We sequence this with ART (Autonomic Response Testing) biofeedback rather than by protocol calendar, because patients arrive at wildly different starting points. A patient in a deep Cell Danger Response state needs months of foundational work; another may be ready in three weeks. Guessing at this is how people get hurt.
The specific blocks we look for before any antimicrobial herb goes in:
Closed drainage
Constipation, poor bile flow, static lymph, low sweat capacity. If the exits are shut, nothing you mobilise leaves. Open drainage first — this is non-negotiable, and it is where most failed protocols failed.
Mast cell activation
The patient who reacts to everything — every supplement, every food, every smell — usually is not failing herbs. They are in mast cell activation, and herbal tinctures in alcohol are a reliable provocation. Stabilise the mast cells and the same herb is often tolerated at the same dose.
Unaddressed mold
Mycotoxin exposure suppresses immune surveillance and disrupts detoxification. In a substantial share of our “treatment-resistant Lyme” patients, mold is the actual primary driver. Kill Borrelia all day in a water-damaged house and nothing changes.
Cell Danger Response
A body in metabolic hibernation cannot execute a recovery. Pushing antimicrobials, peptides or mitochondrial support against an active CDR reliably backfires. Regulation comes before ambition.
Interference fields
Dental cavitations, root-canalled teeth, old scars, tonsil foci. These dysregulate the autonomic nervous system and block healing silently. We have watched years-long “chronic Lyme” resolve after neural therapy to an interference field nobody had looked for.
Parasites
Parasites frequently travel with Lyme, and in some cases harbour spirochetes directly. We often run an antiparasitic layer first, which not uncommonly drops the Lyme burden before we have targeted Borrelia at all.
Only when those are addressed does a herbal protocol get a fair test. Run it earlier and you have not learned that the herb does not work — you have learned that the patient was not ready, which is a completely different piece of information and a much more expensive way to obtain it. Our full sequence is laid out in the terrain-based roadmap for chronic Lyme.
Dry Herb, Tincture, Liposomal: Why the Form Changes Everything
Two patients are both “on Cryptolepis.” One takes two 400 mg capsules of powdered root twice a day. The other takes a half teaspoon of 1:5 tincture three times a day. These are not the same treatment, and pretending they are is how clinical information gets lost.
The difference comes down to three things: how much of the plant’s active chemistry is actually extracted, how fast it enters the bloodstream, and how far into tissue it travels. Each form sits at a different point on all three axes, and each has a job.
Stage one: the dry herb — a tolerance test, not a treatment
Powdered whole herb in a capsule is the least potent form available. That is precisely why we start there.
When a capsule is swallowed, the powder has to be wetted, dispersed and digested before anything is absorbed, and only the fraction of the plant’s constituents that happens to be water-soluble at gut pH makes it across. Absorption is slow, partial and buffered by whatever else is in the stomach. In pharmacological terms this is a weakness. In the first two weeks of a chronic Lyme protocol it is the entire point.
What we are asking at this stage is not “is this herb killing Borrelia?” It is a set of much more basic questions:
- Does this patient have an allergic or mast-cell response to this plant?
- Does it cause gastrointestinal upset at any dose?
- Does a low dose produce a disproportionate die-off reaction — meaning drainage is still not adequate?
- Can the patient remember to take it, afford it, and stay on it?
Answering those with the gentlest available form costs a patient two weeks and about thirty dollars. Answering them with a tincture costs them, sometimes, a month of their life. We have never once regretted starting low.
There is a second, subtler argument for the dry herb, and it applies particularly to Artemisia annua. Whole plant is not a diluted version of the isolated compound — it is a different pharmacological object. Artemisia annua tea and extracts contain flavonoids and polyphenols absent from purified artemisinin, and they behave differently in the liver: purified artemisinin strongly induces CYP2B6 and CYP3A4, while whole-plant extracts in one study induced transcription but did not raise enzyme protein, and in fact inhibited enzyme activity.7 For some plants the whole herb is not simply the weak option. It is a genuinely different medicine.
Stage two: tinctures — where the therapeutic pressure lives
A tincture is the plant material extracted into alcohol, or alcohol and water, usually at a 1:2 to 1:5 ratio of herb to menstruum. Alcohol pulls out compound classes that water alone leaves behind — alkaloids, resins, many of the lipophilic constituents — and it pulls out more of them. It also delivers them into a body that has almost nothing left to do before absorption: the material arrives already dissolved, and a portion is taken up sublingually and through the gastric mucosa within minutes.
Practically, this means three things:
- Broader chemistry. For Cryptolepis in particular, the cryptolepine alkaloids that drive its activity extract far better into alcohol than into water. This is not a marginal difference.
- Faster onset. Minutes rather than hours. Excellent for titration, because you learn quickly; risky for reactive patients, for the same reason.
- Real dose flexibility. You can move a patient from five drops to sixty drops over three weeks. You cannot meaningfully subdivide a capsule.
Tinctures are where most of the actual therapeutic work of a herbal Lyme protocol gets done. They are also the form most likely to provoke a reaction — partly because they are stronger, and partly because of the alcohol itself, which is a frequent trigger in mast-cell-activated patients. For those patients, glycerites, or evaporating the alcohol off in a small amount of hot water for a minute before drinking, often solves the problem without abandoning the form.
Stage three: liposomal — for the deep, stubborn residue
A liposome is a microscopic sphere of phospholipid, the same class of molecule that makes up a cell membrane, with the active compound carried inside or within the lipid layer. The rationale for using them is that this packaging changes how a substance is handled after it is swallowed: it can protect the payload from degradation in the stomach, improve uptake of poorly-absorbed compounds, and — because the carrier is chemically similar to a cell membrane — potentially improve delivery into cells and across lipid-rich barriers rather than merely into the bloodstream.
That is the rationale. The next section deals honestly with which parts of it are supported and which are not, because there is a great deal of overstatement in this corner of the field and our patients deserve better than marketing copy.
In practice, we reach for liposomal preparations in a specific and fairly narrow situation: a patient who has been stabilised, has tolerated dry herb and then tincture, has plateaued at a good tincture dose, and still carries the neurological and deep-tissue end of the picture — the cognitive symptoms, the nerve pain, the joint involvement that has not moved. Liposomal is not where you start. It is where you go when the earlier stages have taken you as far as they can and you need more tissue-level exposure than a tincture is delivering.
Form Comparison at a Glance
| Form | Relative potency | Onset | Best used for | Main limitations | Where it sits in our sequence |
|---|---|---|---|---|---|
| Dry herbcapsule, powder, tea | Lowest. Only water-soluble fraction is absorbed; whole-plant matrix intact. | Slow — hours. Buffered by food and gastric transit. | Tolerance testing. Highly reactive patients. Plants where whole-herb chemistry differs meaningfully from the isolate (Artemisia). | Lipophilic and alkaloid constituents poorly extracted. Large pill burden. Hard to titrate finely. | Weeks 1–3. Always first. Establishes tolerance at minimum risk. |
| Tincture1:2 to 1:5 hydro-alcoholic | Substantially higher. Alcohol extracts alkaloids, resins and lipophilic compounds water leaves behind. | Fast — minutes. Partial sublingual and gastric-mucosal uptake. | The working therapeutic dose. Drop-by-drop titration. Combining several herbs in one dose. | Alcohol content is a frequent MCAS trigger. Taste. Higher Herx risk. Quality varies enormously by maker. | Weeks 3–12+. Where most of the real work happens. |
| Liposomalphospholipid-encapsulated | Highest systemic exposure per milligram for compounds with poor native absorption; little advantage for compounds already well absorbed. | Moderate. Different absorption route, often smoother curve and longer tail. | Deep tissue and neurological presentations after a tincture plateau. Patients who cannot tolerate alcohol. | Expensive. Quality and characterisation are largely unverifiable. Claims routinely outrun evidence (see below). | Later stage only. After stabilisation, tolerance and a genuine tincture plateau. |
| Essential oilsteam-distilled volatiles | Very high potency, entirely different chemistry — not comparable to the extracts above. | Very fast. Highly lipophilic. | Biofilm-directed work (oregano, cinnamon bark, clove, garlic have the best in-vitro persister and biofilm data). | Mucosal irritation. Narrow margin. Must be properly diluted and encapsulated. Not a tincture substitute. | Adjunct. Used selectively, usually alongside a tincture stage. |
Potency comparisons here are qualitative and reflect extraction chemistry and clinical experience, not head-to-head pharmacokinetic studies — which, for these particular herbs in these particular forms, do not exist.
Liposomal Herbs: What Is Real, and What Is Oversold
We use liposomal preparations. We also think the claims made for them in the Lyme world have run well ahead of the evidence, and a guide that repeated those claims uncritically would not be worth writing. So here is our honest reading, claim by claim.
“Liposomal delivery improves absorption” — largely supported, with an important caveat
Phospholipid-based delivery genuinely does improve the oral bioavailability of poorly-absorbed plant compounds. The cleanest human demonstration is silybin from milk thistle: a silybin–phosphatidylcholine complex produced roughly 9.6-fold higher bioavailability than conventional silymarin in healthy volunteers, with peak concentrations of 207 versus 12.6 ng/L.8 Curcumin shows a similar pattern, with formulation-dependent increases ranging from a few-fold for lecithin liposomes up to very large multiples for engineered micelles.9
The caveat is that those studies test specific, characterised, industrially manufactured formulations, most of which are phytosomes or micelles rather than true liposomes — chemically related but structurally distinct. And the benefit is not universal: a 2023 randomised human pharmacokinetic study comparing a commercial liposomal multivitamin against a non-liposomal one found mixed, modest results that did not reach statistical significance overall.10 “Liposomal” on a label is not, by itself, a guarantee of anything.
The practical takeaway: the absorption advantage is real for compounds that are poorly absorbed natively. For a compound that already absorbs well, you are mostly buying expensive packaging.
“Liposomes cross the blood-brain barrier” — this one needs correcting
As a general statement, this is not supported. The blood-brain barrier excludes more than 98% of small-molecule drugs and essentially all macromolecular therapeutics, and plain, unmodified liposomes do not meaningfully cross an intact BBB. Every liposomal formulation in the brain-delivery research literature is surface-engineered for the purpose — transferrin conjugation, antibody decoration, cell-penetrating peptides, receptor-mediated transcytosis ligands.11 An encapsulated herb in a lecithin vesicle has none of that targeting machinery.
We say this plainly because the alternative is worse: patients are being sold an expensive product on a mechanism that does not hold, and when it does not deliver what was promised, they lose faith in the whole approach.
Is there then any legitimate neurological rationale for liposomal herbs? We think there is, but it is a more modest one, and it is worth stating accurately. Higher systemic exposure means a higher concentration gradient across every barrier in the body, including the BBB — more compound presented is more compound available to cross by whatever route it normally uses. Many of the relevant constituents are themselves lipophilic and cross to some degree on their own. And the barrier in a neuroinflammatory patient is frequently not intact; BBB permeability is increased in a range of inflammatory states, which is part of the problem in neuroborreliosis to begin with. That is a reasonable argument for expecting better central exposure. It is not the same as the carrier ferrying the herb across, and it should not be described that way.
“Liposomes penetrate biofilm” — real in the laboratory, unproven in patients
This one has genuine supporting science. Liposomes can move through the water channels of a biofilm matrix, cationic surfaces interact electrostatically with the extracellular DNA that holds the matrix together, and PEGylated liposomes show two- to four-fold higher biofilm permeability than non-PEGylated ones.12 Penetration is best below roughly 130 nm particle size.
Two things follow. First, this work is overwhelmingly in vitro — the authors of the most recent major review state flatly that “at present, there is no approved anti-biofilm agent available.” Second, and more practically: the properties that make a liposome penetrate biofilm are small size, defined surface charge, and a narrow size distribution. Those are manufacturing specifications. They are not things that happen by accident.
Home-made liposomal preparations: our honest position
Dr. Dietrich Klinghardt — with whom I trained directly, and whose clinical work has shaped a great deal of how we practice — popularised a simple method for making liposomal herbal preparations at home. The approach is straightforward: combine a phospholipid base such as Lipowell or BodyBio PC with liquid herbal tinctures (Cryptolepis, Andrographis, Smilax and others) and filtered water, then run the mixture in an ultrasonic sonicator for fifteen to thirty minutes, stirring occasionally. The result is refrigerated and taken a tablespoon or two at a time through the day. A high-speed blender is sometimes suggested as a partial substitute.
Many patients report doing well on these preparations, and the ingredient cost is a fraction of commercial liposomal products. We want to be straightforward about what that does and does not tell us.
There is no published pharmacokinetic data, particle-size characterisation, encapsulation-efficiency measurement or clinical study of kitchen-prepared, ultrasonic-cleaner-sonicated herbal liposomes. The human absorption studies cited for liposomal delivery are for manufactured phytosomes and micelles. The biofilm data requires defined particle size and surface charge. The brain-delivery data requires targeting ligands. None of those parameters can be produced or verified with a household sonicator, which generates large, heterogeneous, multilamellar vesicles of unknown and unmeasurable encapsulation efficiency, with no stability or sterility assurance.
What is likely true is that combining a tincture with a phospholipid improves absorption to some degree — emulsification alone does that, and phospholipids are surfactants. That is a modest and defensible claim. The claims about biofilm penetration and brain delivery are not transferable from the manufactured-liposome literature to a preparation made in a jewellery cleaner, and we do not make them to patients.
Where does that leave the method? We think it is reasonable for patients who are already tolerating tinctures well, who understand what they are and are not getting, and who are using refrigerated batches promptly. We are more cautious about it in immunocompromised patients, where sterility genuinely matters. And when we want the specific advantages that only characterised manufacturing provides, we use a commercial preparation — most often BioPure’s Cocktail liposomal drops, a ready-made liposomal herbal blend — and we accept the cost.
Better absorbed is a real and useful claim. Crosses the blood-brain barrier is not.
The Master Herb Table
This is the reference table we use in-office. Read it with three things in mind.
- The evidence tier refers to laboratory activity, not clinical outcome. No herb in this table has randomised human trial data in Lyme disease. “Strong in vitro” means it killed organisms in a dish at a stated concentration — a meaningful signal, not a proven treatment.
- The dose ranges are starting points for a supervised protocol, not instructions. They are drawn from Stephen Buhner’s published protocols, manufacturer monographs, and common clinical practice, and they vary between sources. Nearly every patient we treat starts below the bottom of these ranges and titrates up over weeks.
- Every column assumes the terrain work above has already been done.
| Herb | Primary target | Key actions | Dry herb / capsule | Tincture | Liposomal use | Key cautions |
|---|---|---|---|---|---|---|
| CryptolepisCryptolepis sanguinolentaStrong in vitro | Borrelia persisters; Babesia | Cryptolepine alkaloids; DNA intercalation; only agent producing complete eradication of stationary-phase B. burgdorferi at 1% in the Hopkins screen (MIC 0.03–0.06%) | Root powder available but uncommon; alkaloids extract poorly into water — not the preferred form | Preferred form. Commonly 1–2.5 mL (approx. ¼–½ tsp) three times daily; Buhner used ½ tsp 3×/day for 30 days in his Babesia protocol | Widely used and reasonable at this stage; a frequent component of home-sonicated blends | Avoid in pregnancy (uterotonic potential). May lower blood pressure and blood glucose — caution with antihypertensives and insulin. Intensely bitter. Strong Herx potential; start at 3–5 drops. |
| Japanese knotweedPolygonum cuspidatumStrong in vitro | Borrelia; neuroinflammation; vasculature | Resveratrol, emodin, polydatin. Anti-spirochetal in vitro; inhibits MMPs and aggrecanases; protects endothelium; improves microcirculation to poorly-perfused tissue where Borrelia hides | Standardised extract (8–50% resveratrol) 500–1000 mg 2–3×/day; Buhner powder dosing runs much higher, 1 tsp to 1 Tbsp 3×/day | ¼–1 tsp, 3–6×/day per Buhner — toward the high end of what most patients tolerate | Resveratrol is poorly absorbed natively, so this is one of the better candidates for liposomal delivery | Antiplatelet effect — caution or avoid with anticoagulants and before surgery. Emodin content causes loose stools at higher doses. May lower blood pressure. |
| Black walnutJuglans nigraStrong in vitro | Borrelia persisters; parasites | Juglone and naphthoquinones; second-strongest botanical in the Hopkins persister screen (approx. 14% residual viability at 1%); long traditional antiparasitic use | Green hull powder 500–1000 mg 2–3×/day, typically in short courses | Green hull tincture 10–30 drops 2–3×/day | Less commonly used liposomally; juglone is already lipophilic | Tree nut allergy is an absolute contraindication. Juglone is GI-irritating; use in pulses rather than continuously. Stains everything. Avoid in pregnancy. |
| Artemisia / artemisininArtemisia annuaStrong in vitro | Babesia; Borrelia persisters; biofilm | Endoperoxide bridge generates reactive oxygen species in iron-rich environments; active against round bodies and biofilm-associated forms; strong antiprotozoal activity | Whole herb 1–2 g/day. Isolated artemisinin 200–600 mg/day divided, pulsed — commonly 3–5 days on, 4–7 days off | Whole-plant tincture ¼–½ tsp 3×/day; note the whole plant is pharmacologically different from the isolate | Artesunate and dihydroartemisinin are the better-absorbed derivatives; liposomal artemisinin is available but the isolate absorbs reasonably well already | Purified artemisinin induces its own metabolism via CYP2B6 and CYP3A4 within two days — the basis for pulsing. Contraindicated in pregnancy. Dizziness and tinnitus at high doses. See the G6PD note below. |
| Cistus incanusCistus incanus / creticusStrong in vitro | Biofilm; Borrelia; viral load | Highly polyphenol-rich. Active against stationary-phase B. burgdorferi in the Hopkins screen (as a 45% ethanol extract). Separate work shows inhibition of oral biofilm formation and blockade of viral envelope attachment | Tea is the traditional and most-used form: 1–2 tsp dried herb steeped 10 min, 2–3 cups daily. Also used as an oral/nasal rinse | Available; 20–40 drops 2–3×/day. Tea is generally preferred for the biofilm indication | Less common; the polyphenols are water-soluble and extract well into tea | Very well tolerated. High tannin content can bind minerals and medications — separate by two hours. Can be drying to mucous membranes. Occasional nausea on an empty stomach. |
| Cat’s clawUncaria tomentosaModerate in vitro | Immune modulation; Borrelia | Pentacyclic oxindole alkaloids. Raises NK cell activity and lymphocyte counts; modest direct anti-spirochetal activity (approx. 49% residual viability at 1% — among the weaker of the seven) | 500 mg capsules, 1–4 capsules 3×/day; Buhner powder 1 tsp 3×/day | ¼–½ tsp 3×/day | Occasionally used; no clear advantage demonstrated | Insist on the pentacyclic chemotype — tetracyclic alkaloids antagonise it. Avoid in pregnancy, in transplant recipients and with immunosuppressants. Theoretical caution in active autoimmunity. |
| Chinese skullcapScutellaria baicalensisModerate in vitro | Neuroinflammation; cytokine control | Baicalin and baicalein. Potent inhibition of inflammatory cytokines and MMPs; crosses into the CNS; synergist that improves other antimicrobials. Weakest of the seven for direct kill (approx. 59% residual viability at 1%) | Standardised extract 500–1000 mg 2–3×/day | ¼ tsp 3×/day, higher in neurological cases; Buhner combined it in equal parts with Chinese red sage | A reasonable candidate — baicalein absorption is limited natively | Sedating for some. Rare hepatotoxicity has been reported with Scutellaria products, most often traced to adulteration with S. lateriflora or germander — source matters. Inhibits several CYP enzymes; check interactions. |
| AndrographisAndrographis paniculataModerate in vitro | Borrelia; viral coinfection | Andrographolide. Anti-spirochetal, antiviral and anti-inflammatory; part of Buhner’s original core protocol, though he de-emphasised it later | Extract standardised to andrographolide, 400–1200 mg/day divided; Buhner escalated to 1200 mg 3×/day, which is high relative to trial doses | Available but capsules are more common for dose precision | Occasionally in home-made blends per Klinghardt’s method | The herb on this list most associated with allergic skin reactions — hives in roughly 1% (Buhner’s own figure); stop and do not restart if they appear. Temporary taste disturbance is reported. Rare serious allergic reactions have led to a warning label in Australia. No credible liver signal. |
| HouttuyniaHouttuynia cordataTraditional / mechanistic | Bartonella; viral | A mainstay of Buhner’s Bartonella protocol rather than his Lyme core. Antiviral and anti-inflammatory; traditional use in Southeast and East Asian medicine | Dried herb as tea, or capsules; dosing not well standardised | ½ tsp 3×/day, usually within a blend | Uncommon | Distinctive fishy odour and taste — a genuine adherence problem. Limited safety data. Mild GI upset common. |
| Sida acutaSida acutaTraditional / mechanistic | Bartonella; Babesia | Protective of red blood cells and endothelium; used by Buhner in coinfection protocols, not in his Lyme core | Powder occasionally used; tincture is standard | 30–60 drops 3–4×/day for Bartonella; ¼ tsp 3×/day for Babesia | Uncommon | Limited safety data. Some Sida species contain ephedrine-type alkaloids — caution in hypertension, arrhythmia, and with stimulants. Species identity and sourcing matter. |
| Olive leafOlea europaeaTraditional / mechanistic | Broad antimicrobial; viral | Oleuropein and hydroxytyrosol. Broad-spectrum antimicrobial and antiviral activity in vitro; not part of the Hopkins Borrelia screen | Extract standardised to 18–20% oleuropein, 500 mg 2–3×/day | 20–40 drops 2–3×/day | Available; modest rationale | Lowers blood pressure and blood glucose — meaningful in patients on antihypertensives or insulin. Notorious for disproportionate die-off reactions; start very low. |
| GarlicAllium sativumStrong in vitro (oil) | Persisters; biofilm | Garlic essential oil sterilised stationary-phase B. burgdorferi cultures at 0.05% in the Hopkins essential-oil screen — among the most potent results in that series. Allicin and ajoene are antimicrobial and antibiofilm | Aged garlic extract or allicin-standardised capsules, 600–1200 mg/day | Rarely used as a tincture | Enteric-coated garlic oil capsules are the form that matches the research; not a true liposome | Antiplatelet — the same anticoagulant and surgical cautions as knotweed. GI burning. Odour. Essential oil must never be taken undiluted. |
| AstragalusAstragalus membranaceusTraditional / mechanistic | Immune terrain; prevention | Not an antimicrobial. Deep immune tonic — supports TH1 function, raises interferon and NK activity, and is used to build the host’s own capacity to contain infection rather than to kill organisms directly | Standardised extract 500–1000 mg 2–3×/day; dried root also used as decoction | ¼–½ tsp 2–3×/day | Uncommon; not needed for a terrain herb | Buhner recommended it strongly for prevention and early Lyme and became more cautious about heavy long-term use in late-stage disease, where immune polarisation is already disturbed. Caution with immunosuppressants and in transplant recipients. |
| Teasel rootDipsacus fullonumInactive in vitro | Musculoskeletal symptoms | Long-standing traditional and European folk use for Lyme-associated joint and connective tissue pain. Mechanism unclear — possibly connective tissue and lymphatic rather than antimicrobial | Root powder, dosing not standardised | Traditionally 3–20 drops 1–3×/day — dosed far lower than the antimicrobial herbs | Not used | Showed no activity in the Hopkins screen (MIC >2%). Included here because it is widely sold for Lyme and patients ask; we do not use it as an antimicrobial. Some patients report symptomatic benefit. |
Evidence key. Strong in vitro substantial activity against stationary-phase B. burgdorferi in published screens. Moderate in vitro activity demonstrated but toward the weaker end of the active group. Traditional / mechanistic used clinically on traditional or mechanistic grounds without direct anti-Borrelia screening data. Inactive in vitro tested and found inactive. None of these tiers denotes clinical efficacy in humans, which has not been established for any of them.
A note on tincture measures. Sources move between drops, millilitres and teaspoons without converting. Roughly: 1 teaspoon ≈ 5 mL ≈ 100–120 drops; ¼ teaspoon ≈ 1.25 mL ≈ 25–30 drops. Concentration also varies with extract ratio — a 1:2 tincture is roughly twice the strength of a 1:5 at the same volume. Always dose from the specific product in hand.
The specific products we use
Quality varies enormously between makers, and with botanicals that variation is not cosmetic — it determines whether the preparation contains a therapeutic amount of the constituent you are after. These are the products we stock and use in our own protocols, available through our dispensary:
The working forms
Cryptolepis (BioPure, 4 oz) — our most-used antimicrobial tincture.
Cistus incanus (BioPure, 4 oz) — biofilm and viral burden.
Andrographis (BioPure, 2 oz) — start low.
Baikalin concentrated extract (BioPure) — concentrated Chinese skullcap.
Where we start
Japanese Knotweed Supreme (Supreme Nutrition, 120 ct)
Scutellaria Supreme (Supreme Nutrition, 90 ct) — Chinese skullcap in whole-herb form.
Astragalus (Nature’s Sunshine) — immune terrain support.
The deep-tissue stage
Cocktail liposomal drops (BioPure, 2 oz) — a ready-made liposomal herbal blend, and the option we reach for most often when a patient plateaus on tinctures and we want commercial-grade formulation rather than a home preparation.
Browse the dispensary
The full range of practitioner-grade botanicals, binders and drainage support is in our online dispensary. If you are an established patient and unsure which form or dose applies to you, ask us rather than guessing — that is precisely what the sequencing in this article is for.
Three Safety Points Worth Getting Right
Andrographis is a useful herb and we use it regularly without incident. It does, however, have one quirk worth knowing about before you start: of all the herbs on this list, it is the one most associated with allergic-type skin reactions.
Stephen Buhner told audiences that roughly 1% of people taking andrographis develop hives that can take a couple of weeks to settle, noting at the time that this appeared nowhere in the published literature. He was right, and the pharmacovigilance data has since caught up with his bedside observation — Australia’s regulator has logged several hundred reports of urticaria, rash and pruritus, along with a distinctive and less-discussed effect, temporary loss or alteration of taste. Rare but serious allergic reactions have also been reported, which is why Australia has required a warning label since 2019.13 Reassuringly, there is no credible liver toxicity signal for andrographis, despite it often being lumped in with herbs that have one.22
In practice this changes very little. We start andrographis low, we tell patients what an allergic reaction looks like, and if hives appear we stop it and do not restart — there are plenty of other herbs on this list. Pushing through a rash is the only real mistake available here.
You will read everywhere that artemisinin is contraindicated in G6PD deficiency. The evidence is weaker than the confidence of that statement suggests.
The G6PD contraindication is rigorously established for the 8-aminoquinolines — primaquine and tafenoquine — which are routinely co-administered with artemisinins in malaria treatment, and the caution appears to have migrated across by association. Post-artemisinin delayed haemolysis is a real, documented phenomenon in severe malaria, but the systematic review of those 37 cases states explicitly that G6PD deficiency was ruled out in all case reports; the proposed mechanism is synchronous clearance of previously parasitised red cells, not oxidative stress in G6PD-deficient cells.14
Our position: screening for G6PD deficiency before artemisinin is a reasonable conservative precaution by extrapolation, and we do it. It is not an evidence-based requirement, and describing it as one misrepresents the literature.
Several of the most-used herbs in this table have real antiplatelet activity — Japanese knotweed and garlic most prominently — and several lower blood pressure or blood glucose (Cryptolepis, olive leaf, knotweed). Stacked together in a multi-herb protocol these effects add up, and the 2023 review of herbal supplements for persistent Lyme symptoms specifically flagged additive risks of bleeding, hypotension and hypoglycaemia.4
Anyone on an anticoagulant or antiplatelet agent, anyone with a bleeding disorder, and anyone heading toward surgery or a dental extraction needs these reviewed individually. This is not a theoretical caution.
Herb-by-Herb: The Six That Do Most of the Work
The table above covers thirteen. In practice, most of our chronic Lyme protocols are built from a core of five or six, chosen by what the patient’s presentation and ART findings point toward. These are the ones worth understanding in more depth.
Cryptolepis sanguinolenta
Ghanaian quinine, yellow-dye root — the strongest laboratory performer
Cryptolepis is a West African climbing shrub whose root has been used in Ghanaian traditional medicine for malaria and fever for generations. It arrived in Lyme practice almost entirely on the strength of the 2020 Hopkins screen, where it did something nothing else in the panel did: at 1%, it eradicated stationary-phase B. burgdorferi completely, with no regrowth after twenty-one days of subculture. Its MIC against growing organisms, 0.03–0.06%, was an order of magnitude below the next botanical.
The active chemistry is a group of indoloquinoline alkaloids, principally cryptolepine, which intercalates into DNA and inhibits topoisomerase — a mechanism quite unlike any standard Lyme antibiotic, which is part of why it reaches organisms that antibiotics do not. Those alkaloids are also why form matters more for Cryptolepis than for almost any other herb here: they extract into alcohol far better than into water, which makes tincture the meaningful therapeutic form and capsuled root powder a relatively weak proxy.
Clinically we find it one of the more reaction-provoking herbs in the cabinet, which is consistent with it being the most active. Patients who start it at a normal dose frequently have a hard week. Patients who start at three drops and build over a month usually do not.
Polygonum cuspidatum
Japanese knotweed, hu zhang — the one we take patients off last
If we had to keep one herb in the whole protocol, it would probably be this one, and the reason has little to do with its direct antimicrobial activity — which is real but middling. Knotweed’s value in chronic Lyme is that it works on the parts of the problem that persist after the organisms are handled.
It inhibits matrix metalloproteinases and aggrecanases, the collagen- and cartilage-degrading enzymes that Borrelia infection upregulates and that do much of the structural damage in Lyme arthritis. It protects endothelial cells. And it improves microcirculation — which matters enormously, because the tissues Borrelia colonises preferentially are exactly the poorly-perfused ones where every other agent you give arrives at the lowest concentration. Knotweed makes the rest of the protocol reach further.
It also crosses into the central nervous system reasonably well, and its anti-neuroinflammatory effect is a large part of why patients report the fog lifting. Buhner considered it the single most important herb in his Lyme protocol, and after years of using it we do not disagree.
Artemisia annua & artemisinin
Sweet wormwood, qinghao — the coinfection workhorse
Artemisinin is a sesquiterpene lactone with an endoperoxide bridge, and that bridge is the whole story. In an iron-rich environment it cleaves and generates a burst of reactive oxygen species — which is why artemisinin is so effective against Babesia, a malaria-like organism that lives inside iron-saturated red blood cells, and why it retains activity against dormant and round-body forms that do not depend on active metabolism to be killed. It also appears to disrupt
Scutellaria baicalensis
Chinese skullcap, huang qin — the synergist
Chinese skullcap is among the weakest direct killers in the Hopkins panel, and it is in almost every protocol we write. That is not a contradiction; it is a different job description.
Baicalin and baicalein are potent inhibitors of the inflammatory cytokine cascade and of the matrix metalloproteinases that damage tissue during infection. Skullcap penetrates the central nervous system well, which makes it particularly useful for the cognitive and neuropsychiatric end of Lyme presentation — the fog, the irritability, the sensory overwhelm. And it behaves as a synergist, improving the performance of antimicrobials given alongside it.
One sourcing point matters more than usual here. Rare hepatotoxicity has been reported with Scutellaria-labelled products, and the cases have most often been traced to adulteration — substitution with American skullcap (S. lateriflora) or, worse, with germander. Buy from suppliers who verify species identity.
Uncaria tomentosa
Cat’s claw, uña de gato — immune modulation rather than kill
Cat’s claw is another herb whose reputation in Lyme rests less on direct antimicrobial power — it was among the weaker actives in the Hopkins screen — than on what it does to the host. It raises natural killer cell activity and lymphocyte counts, which is directly relevant in a population where CD57+ NK cell depletion is a recognised feature of chronic infection.
The critical detail is chemotype. Uncaria tomentosa occurs in two forms: one producing pentacyclic oxindole alkaloids, which are the immune-active fraction, and one producing tetracyclic alkaloids that actually antagonise the pentacyclic ones. A product that does not specify is a coin flip. Insist on pentacyclic-standardised material.
Juglans nigra
Black walnut — the underused second-place finisher
Black walnut hull came second only to Cryptolepis in the Hopkins persister screen, leaving roughly 14% of stationary-phase organisms viable at 1% — a better result than knotweed, Cistus, Artemisia, cat’s claw or skullcap. It is nonetheless one of the least-used herbs in the Lyme world, which we think is a gap.
The active constituents are juglone and related naphthoquinones, which are also responsible for its long traditional use as an antiparasitic — convenient, given how often parasites travel with Lyme. We tend to use it in pulses rather than continuously, because juglone is genuinely irritating to the gut lining at sustained doses.
The absolute contraindication is straightforward and worth stating loudly: anyone with a tree nut allergy should not take black walnut in any form.
A Closer Look at Cistus incanus
Cistus deserves its own section, partly because it is the herb patients ask us about most after Cryptolepis, and partly because the claims made for it are a useful case study in how in-vitro findings turn into marketing.
Cistus incanus is a low Mediterranean shrub, sometimes called rock rose or pink rockrose, traditionally taken as a tea across Greece, Turkey and the Balkans. It is extraordinarily polyphenol-rich — that is its entire pharmacological identity. We have written previously about why Cistus has become such a useful tool in chronic illness, and it remains a regular part of our protocols.
What the research actually shows
Three separate lines of evidence get bundled together when people talk about Cistus and Lyme. They are worth separating, because they are of very different strengths and they concern very different things.
Direct activity
Cistus was one of the seven botanicals active against stationary-phase B. burgdorferi at 1% in the Hopkins screen, with an MIC of 0.25–0.5% against growing organisms.1 Importantly, what was tested was a 45% ethanol extract of the aerial parts — not an essential oil, despite what you will read in many places.
Oral biofilm work
Cistus (as C. creticus) inhibited biofilm formation by Streptococcus mutans and showed low MICs against several oral anaerobes, and a review of herbal interventions in oral biofilm rated cistus tea among the most bactericidal agents studied.17,18 A human in-situ study found effects on the dental pellicle.19
Envelope binding
Cistus extract blocks primary attachment of HIV and filoviruses by binding viral envelope proteins; polyphenol-depleted fractions lose the activity, confirming polyphenols as the active principle, and no resistant virus emerged over 24 weeks.20
The popular argument runs: Cistus kills Borrelia in a dish, plus Cistus disrupts biofilm, therefore Cistus disrupts Borrelia biofilm in people. We unpack this at length in our companion article on biofilm, including the one study that does test Cistus against established rather than merely forming biofilm. Each premise is real. The conclusion is an extrapolation across species, organism, biofilm type and body compartment.
Two specifics matter. First, the oral biofilm studies measured inhibition of biofilm formation, not eradication of established biofilm — clinically these are very different propositions, and the “biofilm buster” claim rests on conflating them. Second, the biofilm work used C. creticus against oral anaerobes, organisms unrelated to Borrelia, in a compartment you can rinse.
And the authors of the antiviral paper deserve quoting, because their restraint is exactly right: “we do not advocate the use of Ci extract as drug on the basis of the results presented in this study.” There is no human outcome data for Cistus in Lyme disease.
Why we still use it
Because the risk-benefit arithmetic is unusually favourable. Cistus is a food-grade herbal tea with an excellent safety record, it costs very little, and it has three plausible mechanisms pointing in a useful direction. When a patient with heavy viral coinfection burden and a suspected biofilm component asks whether it is worth adding, the honest answer is that the evidence is indirect but the downside is close to nil.
We use it as tea — one to two teaspoons of the dried herb steeped ten minutes, two to three cups daily — rather than as a capsule or tincture, for a specific reason: the polyphenols are water-soluble, they extract beautifully into hot water, and tea puts them into sustained contact with the oral and gastrointestinal mucosa, which is where the biofilm data actually comes from. Some patients also use cooled tea as an oral rinse or nasal rinse. That is arguably the application best supported by the published work.
One practical caution: Cistus is tannin-rich, and tannins bind minerals and some medications. Separate it from supplements and prescriptions by about two hours.
We stock Cistus incanus by BioPure for patients who prefer a tincture or want a standardised preparation alongside the tea.
How We Actually Build a Protocol
Everything above is background. This is the part patients want, and it is deliberately not a fixed protocol — because a fixed protocol is the thing that fails.
Stabilise before you start
Nervous system regulation, open drainage, binders, gut work, and any mold or environmental exposure addressed. Mast cell stability if reactivity is present. This phase takes anywhere from three weeks to six months, and skipping it is the single most common reason herbal protocols fail. Our binder selection guide covers the drainage side in detail.
Choose two or three herbs, not nine
We select based on presentation and ART findings: what is the dominant organism, what is the dominant symptom cluster, what does the body indicate it is ready to address. A patient with night sweats and air hunger gets a Babesia-weighted selection. A patient with neuropsychiatric symptoms, sole pain and striae gets a Bartonella-weighted one. Starting nine herbs at once means that when something happens — good or bad — you have learned nothing about which one did it.
Dry herb for two to three weeks
Lowest effective form, one herb introduced at a time, several days apart. We are testing tolerance, not treating infection. If a patient reacts badly here, we have learned something important at minimal cost — usually that drainage is still not open, or that mast cells are unstable.
Move to tincture and titrate slowly
Start at three to five drops. Increase every three to four days as tolerated toward the ranges in the table. Most patients take four to six weeks to reach a working dose, and that is the correct pace. This is where the majority of clinical improvement happens, and where most patients should stay for several months.
Pulse and rotate
Artemisinin is pulsed for pharmacological reasons. We rotate other herbs on a longer rhythm — typically six to eight weeks on, one to two weeks off, or swapping the antimicrobial pair — for a different reason: to give the detoxification system periodic recovery, to reduce adaptation, and to give us a clean read on what is actually holding the patient’s improvement.
Escalate to liposomal only at a genuine plateau
The criteria are specific: tolerating tinctures at a full dose, drainage clearly open, several months of steady progress that has now stopped, and residual deep-tissue or neurological symptoms. If any of those are missing, more delivery is not the answer.
Rebuild — then move to maintenance, not to nothing
Mitochondrial and adrenal support come late, not early — pushed against an active Cell Danger Response they reliably backfire. Restoring immune capacity is also where TruDOSE PRP and EBOO ozone therapy do work no herb can do. But note what this step is not: it is not the point where you stop. Feeling well is the beginning of maintenance, not the end of treatment — and that distinction is important enough that it gets its own section below.
How We Navigate the Herbal Terrain
Everything above assumes you can answer a question that no laboratory test can answer: will this particular patient respond to herbs at all, and if so, in which form?
There is no blood test that predicts whether someone will do better on a dry herb, a tincture or a liposomal preparation. There is no marker that tells you whether Cryptolepis or Japanese knotweed is the right starting point for this person, this month. And there is certainly no test that tells you whether a patient is ready to be treated. Guessing at these is how patients end up with a shoebox.
This is where Autonomic Response Testing (ART) does the work in our practice. Developed by Dr. Dietrich Klinghardt, with whom I trained directly, ART is a biofeedback method that reads the autonomic nervous system’s response to a stimulus — and it lets us ask the body questions that the lab cannot.
What we are actually asking
- Is this patient ready for antimicrobial treatment at all? This is the first question and the most important one. A body that is not ready will not reward you for pressing on.
- What has to be cleared first? Hidden interference fields — dental cavitations, old scars, tonsil foci, jawbone infections — will block a herbal protocol silently and indefinitely. So will unaddressed mold. ART finds these before you waste six months on herbs that never had a chance.
- Which binders, and how much lymphatic support? Drainage is not one-size-fits-all. The binder that suits one patient congests another. ART lets us match the binder and the drainage support to the person before a single antimicrobial goes in.
- Which organism, and at what intensity? The difference between a 10% therapeutic load and a 50% one is the difference between steady progress and a month in bed.
- Dry herb, tincture or liposomal? The staged progression in this article is our default, but ART frequently tells us to move faster, slow down, or skip a stage entirely for a given patient.
When we go deeper — and when we do not use herbs at all
Sometimes the answer is that the microbial burden is simply too high for herbs to make headway. In those cases we can go considerably deeper with Cranial Biotic Technique (CBT), a gentle non-invasive method that combines cranial nerve reflex assessment with energetic patterning to locate and reduce stealth pathogen load. Bringing the burden down first is often what finally lets a herbal protocol work — the same herbs, at the same doses, that did nothing three months earlier.
And sometimes the honest answer is that herbs are not the right tool for this patient. Low Dose Immunotherapy (LDI) works on an entirely different principle — retraining immune tolerance rather than reducing microbial burden — and for a meaningful subset of our patients, particularly the highly reactive ones who cannot tolerate antimicrobials of any kind, it outperforms anything in this article. Homeopathic approaches occupy similar ground. ART is how we determine which of these roads a patient should be on, rather than defaulting everyone down the herbal one because it is the one people have heard of.
ART is a clinical method refined over years of practice, not a laboratory measurement, and we present it as exactly that. Lab results inform us. The body leads the conversation.
The Mistake Almost Everyone Makes: Stopping
If you take one thing from this article, take this one.
Chronic Lyme herbs are not a course of treatment you finish. They are closer to a long relationship, and the single most common way we watch patients lose ground they fought hard for is this: they feel well, they conclude they are done, and they stop.
The logic is completely understandable. You have been taking twelve things a day for fourteen months. You feel good. The bottles are expensive and the routine is tedious. Surely, at some point, you get to be finished? And nothing happens for a few weeks, which seems to confirm the decision. It is only at the six-week or ten-week mark that the joints start talking again, the sleep goes sideways, the fog creeps back at four in the afternoon — and by then most people have stopped connecting the two events.
“I felt great for two months after I stopped. Then it all came back. Did it stop working?”
No. It was working the whole time. That is what the two good months were.
Why this happens
Go back to the persister problem at the top of this article. Chronic Lyme is not an infection you sterilise; it is an infection you contain. Dormant organisms persist in poorly-perfused tissue whether you are treating or not, and what a long-running herbal protocol does is hold the population low enough, and the inflammatory response quiet enough, that your immune system can manage the rest.
Remove that pressure and the organisms are not gone — they are just unopposed. The population climbs slowly back, which is exactly why the relapse takes weeks rather than days to show up, and exactly why patients so rarely connect it to the bottles they put away two months earlier.
I will use myself as the example, because it is the clearest one I have.
I carry a low-grade Lyme burden myself, and I respond particularly well to Cryptolepis. Recently I stopped it — not for any principled reason, I simply came off it. Somewhere between thirty and sixty days later my joints began to ache and my sleep deteriorated. I restarted the Cryptolepis, and both resolved.
I am a clinician who thinks about this every working day, and it still took me a couple of months to join the dots. If it can catch me, it can certainly catch a patient who is busy getting their life back.
What maintenance actually looks like
Maintenance is not the same as treatment, and it should not feel like it. What changes:
- The dose comes down, often substantially. Many patients hold well on a third to a half of the dose that got them there.
- The list gets shorter. Most people maintain on one or two herbs — usually the ones that produced the clearest response during the active phase — rather than the full protocol.
- Rotation continues, but gently. Cycling on and off in planned blocks, rather than continuously, keeps the detoxification system fresh and gives you a periodic read on where you actually stand.
- The timeframe is years, not months. For a long-standing chronic case, we plan on some form of ongoing botanical support indefinitely, revisited periodically. That is not a failure of treatment. It is what containment looks like.
How to come off, if you are going to
Sometimes a trial off herbs is exactly the right thing to do — to find out where you genuinely are, or because a patient has earned a break. We just do it deliberately rather than by drift:
- Taper rather than stop. Halve the dose for a few weeks before stopping entirely.
- Pick the season. Not during a high-stress stretch, a move, a viral illness, or the depths of winter — anything that taxes immune function stacks the deck against you.
- Watch at the right interval. Expect the first signals somewhere between four and ten weeks out, not in the first fortnight. Note them when they appear, and know what your own early signals are — for most people it is the same two or three symptoms every time.
- Restart early and without drama. A relapse caught at week six takes a few weeks to reverse. The same relapse caught at month six can take the better part of a year.
And if you do relapse after stopping, please read it correctly. It does not mean the treatment failed, it does not mean you are back at the beginning, and it does not mean you will be on herbs at full dose forever. It means the containment was real, and you removed it.
Feeling well is not the end of treatment. It is the beginning of maintenance.
Managing Die-Off Without Losing Ground
A Herxheimer reaction is not a sign of success. It is a sign that release has outrun clearance, and it should be treated as a dosing error rather than a milestone.
Mild versions — a day or two of extra fatigue, a headache, some achiness as a dose increases — are expected and usually fine. What is not fine, and what we see constantly in patients arriving from elsewhere, is a week flat in bed. That patient has not been treated harder. They have been set back, their nervous system has learned that treatment means suffering, and their willingness to continue has been spent.
What we do about it
- Back the dose down, do not push through. Return to the last comfortable dose, hold for a week, then increase more slowly. The organisms are not going anywhere.
- Open the exits further. Bowel movements daily without exception, adequate hydration and mineral intake, lymphatic movement, and gentle sweating — sauna or a warm bath — if tolerated.
- Binders, timed away from herbs. Activated charcoal, bentonite, chlorella or a blended binder, taken at least two hours from herbs and medications so you are not simply binding the treatment.
- Alkalinise. Alka-Seltzer Gold or a mineral-buffered vitamin C blunts a significant share of Herx symptoms, and is one of the few interventions that works within an hour.
- Endotoxin support. Smilax (sarsaparilla) has a long history in this role and pairs well with the antimicrobial herbs for precisely this reason.
- Reconsider the premise. A patient who Herxes violently at three drops of anything is telling you the terrain work is not finished. Go back to step one.
One distinction worth making explicitly: a true die-off reaction and an allergic reaction are not the same thing, and confusing them is dangerous. Increasing fatigue, aching and fog over a day or two is die-off. Hives, facial or throat swelling, wheezing, or a rapid rash is allergy — stop the herb, do not retry it, and seek care. This matters most with andrographis, for the reasons described above. Our article on parasite die-off symptoms covers the practical management in more depth.
What Herbs Cannot Do
We would be doing patients a disservice if this article ended without this section.
Herbs cannot substitute for antibiotics in acute Lyme. If you have a recent tick bite, an erythema migrans rash, or an acute febrile illness after a known exposure, you need doxycycline and you need it promptly. Early treatment is genuinely curative and the window is short. Nothing in this article applies to that situation.
Herbs cannot overcome an ongoing exposure. Living in a water-damaged building, an unresolved dental infection, continuing tick exposure — no protocol outruns a source that is still feeding the problem.
Herbs cannot fix what is not infection. A meaningful share of persistent post-Lyme symptoms is immune dysregulation, autonomic dysfunction and endothelial inflammation rather than live organisms. The 2023 review of herbal supplements for persistent Lyme symptoms raised exactly this point — that improvement patients report may reflect anti-inflammatory rather than antimicrobial action.4 We think that is likely true for part of it, and it is not a criticism; it just means the target is different from the one people assume.
Herbs cannot prove they are working. There is no reliable test of cure in chronic Lyme. Serology does not track treatment response, PCR is unreliable when organisms are tissue-sequestered, and CD57 is a rough proxy at best. We are navigating by symptoms, function, and clinical pattern. Anyone who tells you otherwise is selling something.
And the field’s evidence base is thinner than its confidence. Six years after the screening study that launched a thousand protocols, there is still no animal study and no controlled human trial. That should make all of us — practitioners included — hold our conclusions more loosely than the internet does.
We use these herbs because the reasoning is sound and patients improve. That is a good reason. It is not the same as proof.
Frequently Asked Questions
Can I just skip to the liposomal form since it is strongest?
You can, and it is usually a mistake. The dry-herb stage exists to answer a question the liposomal stage cannot: whether your body tolerates this plant at all, and whether your drainage can handle what killing produces. Skipping straight to the most bioavailable form means that if you react, you have no idea whether the problem was the herb, the dose, the form, or the state of your detoxification pathways — and you have lost a week finding out. There is also no evidence that liposomal delivery is necessary for most patients; a great many recover on tinctures.
How long does a herbal Lyme protocol take?
Longer than anyone wants to hear, and the honest answer has two parts. Stabilisation before antimicrobials typically runs three weeks to six months depending on how much terrain work is needed. The active antimicrobial phase is measured in months, not weeks — six to eighteen months is realistic for a long-standing chronic case, with rotation and rest periods built in. But then there is a maintenance phase, usually at a much lower dose and on a much shorter list, and for a genuinely chronic case we plan on that continuing for years rather than months. Patients who improve fastest are almost always the ones who spent the most time preparing before they started killing anything — and the ones who hold their gains are the ones who never fully stopped.
Is Cryptolepis really better than antibiotics?
No, and that claim is a distortion of the study everyone is citing. Cryptolepis eradicated stationary-phase Borrelia in a dish at a concentration roughly two thousand times the mass at which the antibiotics were tested. The accurate statement is that it was active in a model where antibiotics failed, at concentrations whose achievability in human tissue is unknown. That is genuinely interesting. It is not evidence of superiority, and there is no human trial comparing the two.
Can I make liposomal herbs at home with a sonicator?
You can make something. Whether it is a liposome in any meaningful pharmaceutical sense is unknown and unmeasurable in a kitchen. Combining tinctures with a phospholipid such as BodyBio PC or Lipowell almost certainly improves absorption to some degree, because phospholipids are surfactants and emulsification alone helps. What cannot be claimed is the biofilm penetration or brain delivery that requires defined particle size, surface charge and targeting — none of which a household ultrasonic device produces or verifies. If you do it, refrigerate and use batches promptly, and be more cautious if you are immunocompromised.
Why start with only two or three herbs when protocols list a dozen?
Because information is the scarcest resource in a chronic Lyme case. Start nine herbs at once and something will happen — improvement, a reaction, a plateau — and you will have no way to attribute it. Two or three, introduced days apart and titrated deliberately, tell you what is actually working for this patient. Over a year you will cover the same ground as the twelve-herb list, but you will know what did it.
Will I be on these herbs forever?
Not at treatment doses, no — but for a long-standing chronic case, plan on some form of ongoing botanical support rather than a finish line. Maintenance usually means a third to a half of the active dose, on one or two herbs rather than the full protocol, often cycled. The reason is in the biology: chronic Lyme is contained rather than sterilised, so removing the pressure entirely tends to let the population climb back over a period of weeks. Stopping abruptly once you feel well is the most common way we see patients lose hard-won ground.
How do you decide which herbs and which form for a specific patient?
With ART biofeedback, because no laboratory test answers that question. We are asking the body which infection it is prioritising, whether drainage and the nervous system can handle treatment yet, whether there is an interference field or a mold exposure blocking progress, which binders and lymphatic support are needed first, and what intensity the patient can tolerate. ART also tells us when herbs are the wrong tool altogether — some patients do far better on low dose immunotherapy, and some need the microbial burden brought down with Cranial Biotic Technique before any herb will get traction.
Do I need to take a biofilm product alongside these herbs?
Sometimes, and rarely as the first move. Biofilm is a genuine mechanism of antimicrobial tolerance, but the agents sold for it vary enormously in how much evidence sits behind them, and the concentrations at which most of them work in the laboratory are reachable in the gut, mouth and sinus rather than in tissue or bloodstream. There is also a specific reason not to run them alone: releasing organisms from a biofilm without an antimicrobial present is the one configuration the research actively warns against. If we use them, they go in alongside the herbs, not before them. Our companion article on biofilm covers this in full.
Do I still need to treat mold if I have Lyme?
In our experience, frequently the mold is the reason the Lyme will not clear. Mycotoxin exposure suppresses immune surveillance and disrupts the detoxification pathways you need to process die-off. We see patients who have spent years on antimicrobials in a water-damaged house, and nothing moves until the exposure is addressed. If you have both, mold generally goes first.
What about alcohol in tinctures if I cannot tolerate it?
Two workable options. Put the dose in a small amount of just-boiled water and let it stand for a minute or two — most of the alcohol evaporates and the constituents remain. Or use a glycerite, which trades some extraction breadth for tolerability. If alcohol is the problem rather than the herb, this usually solves it. If reactions persist across every form, that points to mast cell activation rather than the tincture.
Should I take these herbs alongside antibiotics?
It can be done and is sometimes appropriate, but it needs supervision. Several of these herbs affect CYP enzymes and can change drug levels; several have antiplatelet or blood-pressure-lowering effects that stack with medications. In our practice we rely on antibiotics rarely, and usually where a specific indication argues for them. If you are combining, the combination should be reviewed by someone who knows both sides of it.
How do I know the herbs are working if there is no test?
By function, honestly. Sleep, cognition, pain, exercise tolerance, how many hours of the day you are upright, how long a flare lasts and how fast it settles. We track these deliberately rather than casually, because the trajectory over eight weeks is far more informative than how any given week felt. Serology will not tell you, PCR is unreliable in tissue-sequestered infection, and CD57 is a rough proxy at best.
Not Sure Which Herbs — or Whether You’re Ready for Any of Them?
If you have a shoebox of half-finished bottles and no idea which of them helped, the problem is usually sequence rather than selection. We use ART biofeedback to identify which infection your body is actually prioritising, whether your drainage can handle treatment yet, and what intensity you can tolerate — then build the protocol from there. First visits run two to four hours, and telemedicine is available.
Further reading: Understanding biofilm in chronic Lyme and mold illness · Cistus incanus · Lyme & coinfections · Why chronic Lyme is hard to diagnose · MCAS & histamine · Low dose immunotherapy. Practitioner-grade supplements are available through our online dispensary.
living. holistic. care.
References & Further Reading
- Feng J, Leone J, Schweig S, Zhang Y. Evaluation of natural and botanical medicines for activity against growing and non-growing forms of B. burgdorferi. Frontiers in Medicine. 2020;7:6. doi:10.3389/fmed.2020.00006
- Feng J, Zhang S, Shi W, Zubcevik N, Miklossy J, Zhang Y. Selective essential oils from spice or culinary herbs have high activity against stationary phase and biofilm Borrelia burgdorferi. Frontiers in Medicine. 2017;4:169. doi:10.3389/fmed.2017.00169
- Feng J, Shi W, Miklossy J, Tauxe GM, McMeniman CJ, Zhang Y. Identification of essential oils with strong activity against stationary phase Borrelia burgdorferi. Antibiotics. 2018;7(4):89. doi:10.3390/antibiotics7040089
- Thompson AM, Hynicka LM, Shere-Wolfe KD. A comprehensive review of herbal supplements used for persistent symptoms attributed to Lyme disease. Integrative Medicine (Encinitas). 2023;22(1). PMID: 37101730
- Diederich J, Szczerba K, Foltin V. Classical versus botanical antibiotics in Lyme borreliosis: an in-vivo, LTT-controlled study. Infectious Diseases Diagnosis & Treatment. 2024;8:268. doi:10.29011/2577-1515.100268 (retrospective, unblinded, laboratory surrogate endpoint — hypothesis-generating only)
- Kuvaldina M, Preston A, McClellan L, Pavlicova M, Brannagan T, Fallon BA. A pilot study of disulfiram for individuals with persistent symptoms despite prior antibiotic treatment for Lyme disease. Frontiers in Medicine. 2025. doi:10.3389/fmed.2025.1549324
- Kane NF, Kiani BH, Desrosiers MR, Towler MJ, Weathers PJ. Artemisia extracts differ from artemisinin effects on human hepatic CYP450s 2B6 and 3A4 in vitro. Journal of Ethnopharmacology. 2022;298:115587. doi:10.1016/j.jep.2022.115587
- Méndez-Sánchez N, Dibildox-Martinez M, Sosa-Noguera J, et al. Superior silybin bioavailability of silybin–phosphatidylcholine complex in oily-medium soft-gel capsules versus conventional silymarin tablets in healthy volunteers. BMC Pharmacology and Toxicology. 2019;20:5. doi:10.1186/s40360-018-0280-8
- Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. Molecular Nutrition & Food Research. 2014;58(3):516–527. doi:10.1002/mnfr.201300724
- Ko J, Yoo C, Xing D, Gonzalez DE, et al. Pharmacokinetic analyses of liposomal and non-liposomal multivitamin/mineral formulations. Nutrients. 2023;15(13):3073. doi:10.3390/nu15133073
- Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y. The blood–brain barrier: structure, regulation, and drug delivery. Signal Transduction and Targeted Therapy. 2023;8:217. doi:10.1038/s41392-023-01481-w
- Panthi VK, Fairfull-Smith KE, Islam N. Liposomal drug delivery strategies to eradicate bacterial biofilms: challenges, recent advances, and future perspectives. International Journal of Pharmaceutics. 2024;655:124046. doi:10.1016/j.ijpharm.2024.124046
- Therapeutic Goods Administration (Australia). Andrographis paniculata (Andrographis) and anaphylaxis — updated safety review and supplementary report. Reports to 31 December 2025.
- Rehman K, Lötsch F, Kremsner PG, Ramharter M. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. International Journal of Infectious Diseases. 2014;29:268–273. doi:10.1016/j.ijid.2014.09.007
- Zang M, Zhu F, Li X, Yang A, Xing J. Auto-induction of phase I and phase II metabolism of artemisinin in healthy Chinese subjects after oral administration of a new artemisinin-piperaquine fixed combination. Malaria Journal. 2014;13:214. doi:10.1186/1475-2875-13-214
- Gordi T, Xie R, Huong NV, Huong DX, Karlsson MO, Ashton M. A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction. British Journal of Clinical Pharmacology. 2005;59(2):189–198. doi:10.1111/j.1365-2125.2004.02321.x
- Hickl J, Argyropoulou A, Sakavitsi ME, et al., Karygianni L. Mediterranean herb extracts inhibit microbial growth of representative oral microorganisms and biofilm formation of Streptococcus mutans. PLoS ONE. 2018;13(12):e0207574. doi:10.1371/journal.pone.0207574
- Karygianni L, Al-Ahmad A, Argyropoulou A, Hellwig E, Anderson AC, Skaltsounis AL. Natural antimicrobials and oral microorganisms: a systematic review on herbal interventions for the eradication of multispecies oral biofilms. Frontiers in Microbiology. 2016;6:1529. doi:10.3389/fmicb.2015.01529
- Hannig C, Spitzmüller B, Al-Ahmad A, Hannig M. Effects of Cistus-tea on bacterial colonization and enzyme activities of the in situ pellicle. Journal of Dentistry. 2008;36(7):540–545. doi:10.1016/j.jdent.2008.04.002
- Rebensburg S, Helfer M, Schneider M, et al. Potent in vitro antiviral activity of Cistus incanus extract against HIV and filoviruses targets viral envelope proteins. Scientific Reports. 2016;6:20394. doi:10.1038/srep20394
- Elsherbiny DA, Asimus SA, Karlsson MO, et al. A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens. Journal of Pharmacokinetics and Pharmacodynamics. 2008;35(2):203–217. doi:10.1007/s10928-008-9084-6
- Worakunphanich W, Thavorncharoensap M, Youngkong S, Thadanipon K, Thakkinstian A. Safety of Andrographis paniculata: a systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety. 2021;30(6):727–739. doi:10.1002/pds.5190
- Buhner SH. Healing Lyme: Natural Healing of Lyme Borreliosis and the Coinfections Chlamydia and Spotted Fever Rickettsioses. 2nd ed. Raven Press; 2015.
- Buhner SH. Healing Lyme Disease Coinfections: Complementary and Holistic Treatments for Bartonella and Mycoplasma. Healing Arts Press; 2013.
- Klinghardt D. Lyme disease reactivated by COVID. Sophia Health Institute lecture, April 2026.
